BNGO · Bionano Genomics, Inc.
$1.56
-0.17 (-9.83%)
At close · Sep 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has prepared cash flows forecasts which indicate that based on the Company’s expected operating losses and negative cash flows, there is substantial doubt about the Company’s ability to continue as a going concern within twelve months after the date that the unaudited condensed consolidated financial statements for the six months ended June 30, 2026, are issued.”View the 10-Q filed Aug 10, 2026
Market Cap
$20.37M
Shares
11.78M
Volume · Sep 30
655.03K
Avg daily vol (3M)
910.17K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.56
Open$1.72
Day$1.53–1.73
52W close$1.06–2.13
Avg vol 30d1.8M
Short int1.1M · 9.7% float · 1.0d
Short vol53%
Last earningsAug 10, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 8, 2026
Est · unconfirmed
· in 5 wks
filed Aug 10, 2026
call held Aug 10, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$30.18M
Trailing 12 months
Net income (TTM)
−$32.16M
Trailing 12 months
Revenue growth YoY
+21.4%
Year over year
Operating margin
-106.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+235.5%
Year over year · more shares
Price change (1Y)
+1.2%
Trailing year
Short interest
9.7%
Latest settlement · 1.0 days to cover
AI Brief
Q2 FY26 earnings call · Aug 10, 2026
Q2 FY26
TL;DR. Bionano reported Q2 2026 revenue of $8.2 million, up 21% year-over-year and above guidance, with record flow cell sales of 9,219 units (+27%), driven by clinical adoption. The company raised the low end of full-year 2026 revenue guidance to $31–$33 million and initiated Q3 guidance of $8.2–$8.6 million, while retiring its senior secured convertible debt.
Bullish
- + Q2 revenue beat guidance and grew 21% year-over-year to $8.2M, with consumables up 31%
- + Record flow cell sales of 9,219 units, up 27% year-over-year, driven by clinical adoption
- + Gross margin reached a record 53% in Q2 2026, up from 52% a year ago
- + Raised the low end of full-year 2026 revenue guidance to $31–$33M
- + Fully retired outstanding senior secured convertible debt, simplifying the balance sheet
- + International revenue now represents the majority of total revenue, reflecting global clinical adoption
Bearish
- − Top end of full-year 2026 revenue guidance was not raised due to flow cell manufacturing constraints
- − Demand continues to outpace manufacturing capacity, creating a backlog
- − Software revenue declined 16% year-over-year on deployment timing delays
- − Q3 guidance of $8.2–$8.6M implies flat to modest sequential growth despite strong Q2 momentum
- − Cash runway extends only into Q1 2027, signaling ongoing capital needs
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Very Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+23%
above
Price vs 50-day avg
+20%
above
RSI (14)
55
neutral
MACD trend
Negative
52-week position
47%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+28%
trailing
6-month return
+34%
trailing
YTD return
+2%
this year
Relative strength
+22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +9 funds added
Insider flow
Accumulating
Net +$9.7K over 90 days · 0% sells
Short interest
Falling
9.72% of float · ▼ -6.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
34 holders — mid 3-yr range
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
+26%
Y/Y
EPS growth
+94%
Y/Y
Free cash flow
$-16.3M
Balance sheet
$22.1M
net cash
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−50%
past year
ATR
9.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 10, 2026
Revenue guidance
· Q3 2026
Initiated
$8.2M – $8.6M
prior qtr $8.17M
midpoint +2.8% QoQ
Guided vs delivered
· last 5 settled
Revenue
full year 2024
guided $36M – $40M
$30.78M
Miss −19.0%
Revenue
third quarter of 2024
guided $7.9M – $8.9M
$6.07M
Miss −27.7%
Revenue for the second quarter of 2024
second quarter of 2024
guided $7.8M – $8.2M
$7.77M
Miss −2.9%
Q1 2024 revenue
Q1 2024
guided $8.25M – $8.75M
$8.77M
Beat +3.2%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+23%
Bullish
Price vs 50-day avg
+20%
Bullish
RSI (14)
55
Neutral
MACD trend
Negative
Bearish
52-week position
47%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross)
Golden cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +9 funds added
Insider flow
Accumulating
Net +$9.7K over 90 days · 0% sells
Short interest
Falling
9.72% of float · ▼ -6.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
34 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 47%
Range high $2
vs 200-day avg +23%
vs 50-day avg +20%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| adjusted operating expense non-GAAP | $8.7M | Q2 2026 | — |
| nanochannel array flow cells sold | 9,219 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BNGO
this stock
Bionano Genomics, Inc.
|
$20.37M | +2.0% | +26.3% | — | 9.7% |
|
ISRG
Intuitive Surgical Inc
|
$143.14B | -28.2% | +20.5% | 46.5 | 2.3% |
|
BDX
Becton Dickinson & Co
|
$49.57B | — | +8.2% | — | 4.2% |
|
MDLN
Medline Inc.
|
$45.62B | -17.4% | +11.5% | — | 3.1% |
|
RMD
Resmed Inc
|
$32.02B | -8.2% | +13.4% | 21.3 | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BNGO | -8.2% | +27.9% | +34.5% | +27.9% | +2.0% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -7.6% | +27.8% | +22.3% | +28.5% | -9.9% |